Budget impact analysis of Jivi ® (damoctocog alfa pegol, BAY 94-9027) in severe Hemophilia A in Japan.
CONCLUSIONS: BAY 94-9027 can reduce total severe HA treatment costs, driven by lower annual rFVIII utilization, and a narrow weekly dosing range compared to competitor products in the Japanese market.
PMID: 33459088 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Bleeding | Clinical Trials | Databases & Libraries | Economics | Genetics | Haemophilia | Health Insurance | Health Management | Hemophilia | Insurance | Japan Health | Study